Glioblastoma multiforme (GBM) is one of the most aggressive human brain malignancies. Even with optimal treatment, median survival is less than six months for patients with recurrent GBM. Immune-based therapies have the potential to improve patient outcome by supplementing standard treatment. Expression of human cytomegalovirus (CMV) antigens in GBM tissues provides the unique opportunity to target viral antigens for GBM therapy. Here we report findings of a formal clinical assessment of safety and potential clinical efficacy of autologous CMV-specific T cell therapy as a consolidative treatment for recurrent GBM. From a total of 19 recurrent GBM patients, CMV-specific T cells were successfully expanded from 13 patients (68.4%) and 11 of whom received up to four T cell infusions. Combination therapy based on T cell infusion and chemotherapy was well tolerated and we detected only minor adverse events. The overall survival of these patients since first recurrence ranged from 133 to 2428 days with a median overall survival of 403 days. Most importantly, four out of 10 patients that completed the treatment remained progression free during the study period. Furthermore, molecular profiling of CMVspecific T cell therapy from these patients revealed distinct gene expression signatures which correlated with their clinical response. Our study suggests that that a combination therapy with autologous CMV specific T cells and chemotherapy is a safe novel treatment option and may offer clinical benefit for recurrent GBM patients.
Introduction
Glioblastoma multiforme (GBM) is one of the most malignant human adult brain tumours. Current treatment regimes include surgical resection, radio-and chemotherapy, but patient prognosis remains poor with a median survival after initial diagnosis of less than 15 months (1) and a 5-year survival rate of less than 10% (2) .
GBM is incurable and inevitably recurs after initial therapy. Median survival for recurrent GBM is 3-6 months and most patients do not survive longer than one year (2) (3) (4) . While chemotherapy, especially the introduction of temozolomide, has been shown to increase survival to some degree(1), dramatic improvements in outcome for patients with GBM have remained elusive. Therefore, much interest has focused on immunotherapeutic approaches. Strategies under investigation include tumour lysate vaccines, tumour antigen vaccines and targeting of immunomodulatory molecules (reviewed in (5)).
Accumulating evidence indicates human cytomegalovirus (CMV) as a contributing factor to glioma progression (6, 7) and CMV has been suggested as a therapeutic target (8) . While not classified as an oncogenic virus, CMV can increase cellular proliferation, angiogenesis and immune evasion, thus enabling several hallmarks of cancer (9, 10) . Recently, an onco-accessory function of CMV has also been described in a mouse model of glioblastoma using murine cytomegalovirus infection (11) . More importantly, CMV antigens and nucleic acids have been detected in histological sections of GBM but not in surrounding healthy tissue (12) (13) (14) (15) (16) (17) (18) . Although one patient with dendritic cells pulsed with autologous GBM lysate elicited a CMVspecific immune response, further supporting the presence of CMV antigens in GBM tissue (24). This provides an opportunity to target viral antigens with immune-based therapies. Low levels of CMV antigen expression in tumour cells were found to be associated with longer survival of GBM patients (15, 16), thus indicating that antiviral therapy could improve GBM prognosis. Additionally, recent studies supplementing standard GBM therapy with antiviral valganciclovir treatment for more than 6 months demonstrated a survival benefit for GBM patients (25, 26).
We have explored the feasibility and safety of an autologous T-cell based GBM immunotherapy targeting CMV antigens. We have recently shown that CMV-specific
CD8
+ T-cells in GBM patients have reduced functional capacity, but that this limitation can be reversed following in vitro stimulation. Adoptive transfer of these cells into a single patient with recurrent GBM in combination with standard chemotherapy was associated with long term disease-free survival (27). Here, we report the findings from a formal clinical assessment of this initial finding as a Phase I clinical trial. We demonstrate that autologous CMV-specific T-cell therapy is safe with minimal side effects and may offer clinical benefit for recurrent GBM patients.
Research. 
Materials and Methods

Study design, Ethics and patients
This phase I clinical study was designed to assess the safety and tolerabilty of autologous CMV-specific T-cell therapy for recurrent GBM. This clinical trial was conducted according to Declaration of Helsinki principles and was approved by The
QIMR Berghofer Medical Research and Uniting Care Health Human Research Ethics
Committees. All participants signed a consent form which was approved by both ethics committees. This study is registered under the Australia New Zealand Clinical Trial Registry (ACTRN12609000338268). Study completion required a minimum of three T cell infusions, whereas additional infusions could be administered depending on availability of cells. Infusions consisting of 25 -40 x 10 6 autologous CMV-specific T-cells in sterile saline were administered in 4 (+/-2) week intervals. The infusions were coordinated with periods of chemotherapy to avoid unwanted side effects. Peripheral blood samples collected prior to each infusion and at regular intervals post-infusion were used for haematological and immunological monitoring. Each follow-up visit included vital observations and a quality-of-life questionnaire. Magnetic resonance imaging (MRI) was used to assess baseline tumour load prior to infusion and at regular intervals after first infusion.
In vitro expansion of CMV-specific T-cells from GBM patients
CMV-specific T-cells were generated by in vitro stimulation with synthetic peptide sensitized with CMV peptides (5μg/ml; Suppl Table S1 ) at a responder to stimulator ratio of 2:1 in growth medium. After 3 days and then every 3 to 4 days thereafter, the cultures were supplemented with growth medium containing 120IU/ml recombinant interleukin-2 (IL-2; Komtur Pharmaceuticals). Cells were cryopreserved on day 14, after testing for sterility and CMV-specific T-cells using an IFN-γ intracellular cytokine assay.
Release criteria were ≥ 0.1% CMV specific T-cells in total lymphocyte population and >50% cell viability.
Characterization of CMV CTL by intracellular cytokine assay and flow cytometry
PBMCs or cultured T-cells were stimulated with peptides corresponding to defined PBMCs were revived from cryopreserved stocks and stained with appropriate CMVdextramers, followed by staining for surface markers to allow for separation of monocytes, B cells and T-cells. After filtering the cell suspension through a nylon mesh for removal of cell clumps, total CD8+ T-cell and CMV specific CD8 + T-cell populations were isolated using a FACS Aria (BD Biosciences) cell sorter. Total RNA was purified using Qiagen RNeasy Micro kit. An RNA amount equivalent to 3000 cells was transcribed into cDNA using the high-capacity-RNA-to-cDNA-Kit. The cDNA was preamplified with a custom primer pool, loaded into custom designed taqman array cards and run on the Viia7 real-time PCR system (all reagents from Life Technologies).
The array cards were designed to contain 93 genes that were described to be regulated in CD8 T-cells during CMV infection(28). Data was normalized to housekeeping genes (18S, actin, ß2-microglobulin) and analyzed using Gene Spring v12.5 software.
Statistical analysis
Mortality and progression-free survival were characterised using Kaplan-Meier curves, and the corresponding median survival times were obtained for the intention-to-treat 
Results
Patient Characteristics
Nineteen patients with recurrent GBM were recruited for this study. Eligibility criteria for the study included (a) Age 18 years or above; (b) Geographically accessible for follow up; (c) ability to provide informed consent; (d) ECOG performance status 0, 1, 2 or 3); (e) life expectancy of at least 3 months (f) positive CMV serology and (g) Previous histological diagnosis of GBM (WHO grade IV) and radiological and/or clinical evidence of tumour progression or recurrence. Four patients had to be withdrawn before venesection due to progressive disease, while insufficient CMV-specific T cells were expanded from two patients due to low precursor frequency or poor cell viability. All patients received standard treatment with maximal safe surgical debulking at primary diagnosis, external beam radiotherapy and chemotherapy (Table 1) . CMV-specific Tcells were successfully expanded from 13 patients, but two patients had to be withdrawn due to progressive illness and one patient discontinued the intervention after two infusions due to progressive disease. In total, 10 patients completed a minimum of three infusions as required per protocol (Table 2) .
In vitro expansion and functional characterization of CMV-specific CD8+ T-cells
Autologous CMV-specific T-cells were successfully expanded from 13 out of 19 patients ( Table 2) . Ex vivo analysis of CMV-specific T-cells from GBM patients using peptide-MHC (pMHC) multimers showed antigen-specific T-cell frequencies ranging Table S2 ). Phenotypic characterization showed that these T cells were predominantly CD3 + with a combination of both CD8 + and CD4 + T-cells (Fig. 1C) . The majority of CMV-specific T-cells were CD45RA -CD27 + and/or CD57 + a phenotype characteristic of effector cells (Fig. 1D) . Intracellular cytokine analysis revealed that high proportions of these in vitro expanded CD8 + T-cells expressed IFNγ in response to stimulation with CMV epitopes (Fig. 1E and F) .
Furthermore, in-depth functional analysis of these T cells from some patients showed that these cells displayed polyfunctional profile and also expressed CD107 (data not shown).
Safety and clinical evaluation of CMV-specific T-cell-based immunotherapy for recurrent GBM
Of the 13 patients for whom CMV-specific T cells were generated, 10 patients received three to four T cell infusions (2-4 x 10 7 cells/infusion, Table 2 ). One patient only received two infusions, whereas two patients died prior to the availability of T cells. Infusions were generally well tolerated and mostly minor adverse events were recorded ( Table 3 ). The toxicity grading was assigned according to the National Cancer analyses indicate that autologous CMV-specific T-cell infusions are a safe treatment for GBM. The median overall survival (OS) of the 11 patients that received at least one infusion was 403 days (range: 133 to 2428 days, Fig. 2A ). The time to progression for all patients after infusion ranged from 108 to more than 1783 days, with a median of 246 days (Fig. 2B) . Of the 11 patients treated with T cell therapy, four patients remained progression-free (Table 2 ). Patient GBM:01 showed the longest stabilization of disease with almost four years of progression-free survival (PFS) after the T-cell infusion. This patient had no other treatment subsequent to CMV-specific T-cell therapy and remains disease-free to date.
Immunological and molecular analysis of CMV-specific T-cell therapy
To assess the efficiency of T-cell therapy, we first determined the effect of antigen-specific T-cell frequencies on survival. However, there was no correlation between the number of CMV-specific T cells transferred and the overall survival and progression-free survival (Fig 3A & B) . Ex vivo longitudinal analysis of CMV-specific T cells showed that although in some patients there was a small increase in the precursor frequency of CMV-specific T-cells, the number of antigen-specific T cells returned to baseline after the completion of adoptive immunotherapy (suppl. Fig. S1A & B). The functional profile of these T-cells also remained unchanged during and after the completion of T-cell therapy (suppl. Fig. S1C ).
We next explored the possibility that gene expression profiling of T-cell therapy may help to distinguish patients that might benefit from adoptive immunotherapy. To test this hypothesis, we used a custom array which allowed quantitative expression analysis of different categories of genes relevant for T cell function (Suppl. 
This expression profiling revealed that 47 out of 93 genes were significantly changed in CMV-specific CD8 + T-cells following in vitro expansion (Fig. 3C and suppl. Fig. S2A and   B ). This gene expression profile was consistent with a signature of activated T-cells and was further confirmed by specific antibody staining and flow cytometry (suppl. Fig.   S2C ).
To identify gene expression patterns that might be of prognostic value, we divided our patient cohort into two groups: (a) GBM patients who had short PFS (<100 days) and (b) GBM patients who either remained progression-free within the study period or developed progressive disease after more than 100 days. In depth analysis of gene expression data revealed that these two groups of patients showed significant differences in the expression of seven genes including T-cell transcription factors resection. We isolated T-cells from the resected tumour tissue and were able to detect CMV-specific CD8 + T-cells (Fig. 4A, upper panel) . However, the majority of these antigen-specific T-cells failed to express multiple cytokines including IFN-, TNF, IL-2 and showed poor cytotoxic activity as assessed by CD107a mobilization following stimulation with CMV peptides (Fig. 4A, lower panel) . Furthermore, staining of CD103 as a marker for tissue resident T-cells (T rm ) revealed that while approximately one third of CD8 + T-cells in the tumour tissue were T rm , none of the CMV-specific T-cells expressed CD103 (Fig. 4B) . The frequency of CMV-specific T-cells in the tumour tissue was approximately four-fold lower when compared to T-cells circulating in peripheral blood at different time points before (d0), during (d35) and after T-cell therapy (d78 and d121, Fig. 4C ). Tumour infiltrating CMV-specific T-cells expressed higher levels of PD-1, TIM-3 and CTLA-4 and lower levels of transcription factors T-bet, Eomes and LEF-1 (Fig. 4C ). These observations suggest that tumour infiltrating antigen-specific T-cells in this GBM patient displayed poor functional capacity and increased expression of inhibitory receptors when compared to T-cells from peripheral blood. Similar expression patterns of PD-1, CTLA-4, TIM-3 and transcription factors were detected in the global CD8 + T cell population (suppl. Fig. 3 ). We further detected almost 5-fold higher levels of regulatory T-cells (CD4+CD25+FoxP3+) than in peripheral blood which is consistent with an immunosuppressive environment in tumour tissue (Fig. 4C ).
Discussion
The survival of patients with recurrent GBM remains poor despite use of all currently available cytotoxic therapeutics (1, 29- In the present study we report the outcome of the first clinical trial for adoptive immunotherapy using CMV-specific T-cells in recurrent GBM patients. We recruited 19 recurrent GBM patients and of these 11 patients received multiple infusions of autologous in vitro expanded CMV-specific T-cells. A number of important conclusions can be drawn from this study. First, adoptive transfer of CMV-specific T-cells was completely safe with minimal toxicities. Although the CMV-specific T-cell therapy was provided in combination with standard therapies (Table 2) , we did not observe any deleterious impact of these therapies on the adoptively transferred CMV-specific T- 
expression of CD103 which is a crucial marker for tissue residence. In addition, these Tcells showed increased expression of checkpoint inhibitory receptors when compared to the circulating effector cells from peripheral blood, potentially reflecting the impact of the tumour microenvironment. We further detected higher amounts of regulatory T cells which might contribute to immunosuppression in GBM tissues (43) . These observations were supported by gene expression analysis of antigen-specific T-cells used for adoptive immunotherapy. Indeed increased prolonged PFS was co-incident with lower expression of checkpoint inhibitory receptors and increased expression of T-cell transcription factors crucial for T-cell function. It is important to emphasize that these observations will require more in-depth analyses in a larger cohort of patients within a randomized Phase II clinical study.
Taken together, adoptive immunotherapy of recurrent GBM patients with CMV-specific T-cells is safe and may provide long-term clinical benefits. These studies provide an important platform for a formal assessment of adoptive T-cell immunotherapy in both therapeutic and prophylactic settings. CMV-specific T-cellbased immunotherapy should be considered as a consolidative treatment following primary diagnosis of GBM for the prevention of recurrent disease.
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